Spots Global Cancer Trial Database for egfr mutation

Every month we try and update this database with for egfr mutation cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Erlotinib Therapy and Subsequent Development of Mechanisms of Secondary Resistance in Patients With NSCLC	NCT00997334	Non-small Cell ...	Erlotinib	18 Years -	Dana-Farber Cancer Institute
Atezolizumab and Bevacizumab in EGFR Mutant NSCLC in Patients With Progressive Disease After Receiving Osimertinib	NCT04099836	Non Small Cell ...	Atezolizumab Bevacizumab	18 Years -	Duke University
Erlotinib in Post Radical Operation NSCLC Patients With EGFR Mutation	NCT01683175	Non-small Cell ...	Erlotinib cis-platinum Vinorelbine	18 Years - 75 Years	Tianjin Medical University Cancer Institute and Hospital
Glutamine Plus L. Reuteri Prevents TKI Therapy-diarrhea in Patients With NSCLC	NCT05852990	Non-Small Cell ...	Glutamine plus ...	18 Years - 80 Years	Instituto Nacional de Cancerologia de Mexico
A Randomised Phase II Trial of Osimertinib With or Without SRS for EGFR Mutated NSCLC With Brain Metastases	NCT03497767	Metastatic Non ...	Osimertinib Stereotactic Ra...	18 Years -	Trans Tasman Radiation Oncology Group
A Study of TAS3351 in NSCLC Patients With EGFRmt	NCT05765734	Non-Small Cell ...	TAS3351 oral ad...	18 Years -	Taiho Oncology, Inc.
Erlotinib in Post Radical Operation NSCLC Patients With EGFR Mutation	NCT01683175	Non-small Cell ...	Erlotinib cis-platinum Vinorelbine	18 Years - 75 Years	Tianjin Medical University Cancer Institute and Hospital
Preoperative Gefitinib for EGFR Mutant II-IIIa NSCLC (ECTOP-1001)	NCT01833572	Non-small-cell ...	Gefitinib	18 Years -	Fudan University
Phase I Trial of Afatinib (BIBW 2992) and Dasatinib in Non-small Cell Lung Cancer (NSCLC)	NCT01999985	Lung Cancer Non-small Cell ...	Dasatinib - 1A Afatinib - 1A Dasatinib - 1B Afatinib - 1B	18 Years -	H. Lee Moffitt Cancer Center and Research Institute
NOV120101 (Poziotinib) for 1st Line Monotherapy in Patients With Lung Adenocarcinoma	NCT01819428	Adenocarcinoma ... Adenocarcinoma ...	NOV120101 (Pozi...	20 Years -	National OncoVenture
Prevalence of EGFR Mutations in epidermoïd Bronchopulmonary Cancers in Réunion Island	NCT04261725	Squamous Cell L...	EGFR mutation	18 Years -	Centre Hospitalier Universitaire de la Réunion
Neoadjuvant Lazertinib Therapy in EGFR-Mutation Positive Lung Adenocarcinoma Detected by BALF Liquid Biopsy	NCT05469022	Non Small Cell ...	Neoadjuvant laz...	19 Years -	Konkuk University Medical Center
To Evaluate the Efficacy of Afatinib in Advanced Lung Squamous Cell Carcinoma With EGFR Sensitive Mutation	NCT04132102	Lung Squamous C...	Afatinib	18 Years -	Shanghai Chest Hospital
Intercalating and Maintenance Gefitinib in Combination With Chemotherapy for Advanced EGFR-mutant NSCLC	NCT02299765	Non-small Cell ... EGFR Activating...	Gefitinib gemcitabine carboplatin	18 Years - 75 Years	Sichuan University
Prevalence of EGFR Mutations in epidermoïd Bronchopulmonary Cancers in Réunion Island	NCT04261725	Squamous Cell L...	EGFR mutation	18 Years -	Centre Hospitalier Universitaire de la Réunion
Erlotinib in Combination With Cetuximab	NCT00895362	Advanced Cancer...	Erlotinib Cetuximab	18 Years -	M.D. Anderson Cancer Center
A Real-world Study of Adjuvant Therapy in Early Stage NSCLC With EGFR Mutation-Positive in China	NCT04830826	NSCLC, Stage I NSCLC, Stage II NSCLC, Stage II...	Surgeries	-	The First Affiliated Hospital of Guangzhou Medical University
Neoadjuvant Immunotherapy in EGFR-mutant Localized NSCLC	NCT05244213	Non-small Cell ... EGFR Activating...	Sintilimab Carboplatin Nab paclitaxel	18 Years - 75 Years	Guangdong Provincial People's Hospital
Observational Study of Patients With Locally Advanced or Metastatic NSCLC (Non-Small Cell Lung Cancer)	NCT03053297	Carcinoma, Non-...	Patient Reporte...	18 Years -	AstraZeneca
Phase III Study of Nazartinib (EGF816) Versus Erlotinib/Gefitinib in First-line Locally Advanced / Metastatic NSCLC With EGFR Activating Mutations	NCT03529084	Carcinoma, Non-...	EFG816 erlotinib or ge...	18 Years -	Novartis
First-line Treatment With Icotinib in Elder NSCLC EGFR Mutated Patients	NCT01646450	Non-Small Cell ...	Icotinib	70 Years - 80 Years	Betta Pharmaceuticals Co., Ltd.
Cryotherapy Combine Icotinib for Advanced NSCLC Treatment	NCT02744664	Lung Neoplasms	Cryotherapy Icotinib	18 Years - 75 Years	Fuda Cancer Hospital, Guangzhou
Induction Chemotherapy Followed by CCRT According to EGFR Mutation Status in NSCLC III	NCT00620269	Lung Cancer NSCLC	Erlotinib Induction or co... CCRT with IP ch... CCRT	18 Years -	National Cancer Center, Korea
Nitroglycerin Plus Radiotherapy Versus Conventional Radiotherapy in Patients With Lung Cancer.	NCT06238882	Non-small Cell ... Brain Metastase... EGFR Gene Mutat...	Nitroglycerin	18 Years - 85 Years	Instituto Nacional de Cancerologia de Mexico
NOV120101 (Poziotinib) for 1st Line Monotherapy in Patients With Lung Adenocarcinoma	NCT01819428	Adenocarcinoma ... Adenocarcinoma ...	NOV120101 (Pozi...	20 Years -	National OncoVenture
A Study to Learn About How Food and Esomeprazole Affect the Level of BAY2927088 in the Blood When Taken Together in Healthy Participants	NCT06378658	Advanced Non-sm... EGFR Mutation HER2 Mutation Healthy Volunte...	BAY2927088 Esomeprazole Food	18 Years - 55 Years	Bayer
Neoadjuvant Lazertinib Therapy in EGFR-Mutation Positive Lung Adenocarcinoma Detected by BALF Liquid Biopsy	NCT05469022	Non Small Cell ...	Neoadjuvant laz...	19 Years -	Konkuk University Medical Center
A Study of BPI-7711 Capsule in Non-small Cell Lung Cancer Patients	NCT03866499	NSCLC	BPI-7711 Gefitinib Placebo Tablet Placebo capsule	18 Years -	Beta Pharma, Inc.
Conmana Combined With Thalidomide to Treat NSCLC	NCT02778893	NSCLC	Conmana Thalidomide	18 Years - 75 Years	Henan Provincial People's Hospital
the Efficacy and Safety of Anlotinib Combined With Almonertinib in the First-line Treatment of Patients With Brain Metastases From EGFR Mutation-positive Non-small Cell Lung Cancer	NCT04978753	Non-small Cell ... Brain Metastase...	Anlotinib	18 Years - 75 Years	Sun Yat-sen University
A Randomised Phase II Trial of Osimertinib With or Without SRS for EGFR Mutated NSCLC With Brain Metastases	NCT03497767	Metastatic Non ...	Osimertinib Stereotactic Ra...	18 Years -	Trans Tasman Radiation Oncology Group
Real-world Analysis of Workup at Disease Progression and Implementation of Osimertinib for EGFR+ NSCLC	NCT04105153	EGFR Positive N...		18 Years -	Thoraxklinik-Heidelberg gGmbH
Neoadjuvant Lazertinib Therapy in EGFR-Mutation Positive Lung Adenocarcinoma Detected by BALF Liquid Biopsy	NCT05469022	Non Small Cell ...	Neoadjuvant laz...	19 Years -	Konkuk University Medical Center
Combination of Cetuximab and NK Immunotherapy for Recurrent Non-small Cell Lung Cancer	NCT02845856	Recurrent Non-s...	Cetuximab NK immunotherap...	30 Years - 70 Years	Fuda Cancer Hospital, Guangzhou
A Study to Assess the Efficacy of Erlotinib for Leptomeningeal Carcinomatosis in EGFR Mutation Positive Non-small Cell Lung Cancer	NCT00830245	Leptomeningeal ... Non-small Cell ...	Erlotinib	18 Years -	Clinical Research Center for Solid Tumor, Korea
An Open Label Study of BIBW 2992/Afatinib in Advanced Non-Small Cell Lung Cancer Patients Pre-treated With Erlotinib or Gefitinib	NCT01932229	NSCLC	Afatinib treatm...	-	Sheba Medical Center
Osimertinib as 1st Line Therapy for Patients With Advanced EGFR Positive Non-Small Cell Lung Cancer	NCT05127382	Lung Cancer Non...		18 Years -	Hellenic Cooperative Oncology Group
Neo-DIANA: Neoadjuvant Treatment for EGFR Mutated Patients	NCT04512430	Non Small Cell ... EGFR Gene Mutat...	Atezolizumab Bevacizumab Carboplatin Pemetrexed	18 Years -	Fundación GECP
Study Comparing Bevacizumab + Erlotinib vs Erlotinib Alone as First Line Treatment of Patients With EGFR Mutated Advanced Non Squamous Non Small Cell Lung Cancer	NCT02633189	Non-squamous No...	Erlotinib Bevacizumab	18 Years - 70 Years	National Cancer Institute, Naples
Almonertinib Combined With Anlotinib as First-line Treatment for Advanced Non-small Cell Lung Cance	NCT06043973	Advanced Non-sm...	almonertinib	18 Years - 75 Years	Qianfoshan Hospital
A Multicenter Randomized Phase III Study Comparing Second-line Treatment With Chemotherapy Associated or Not to Erlotinib in NSCLC Patients With Secondary Resistance to TKI-EGFR	NCT02178397	NSCLC Patients ...	ERLOTINIB WITH ... CHEMOTHERAPY ON...	18 Years -	Centre Francois Baclesse
Phase 2 Study of AUY922 in NSCLC Patients With Exon 20 Insertion Mutations in EGFR	NCT01854034	Non Small Cell ...	AUY922	18 Years -	Massachusetts General Hospital
Icotinib With Concurrent Radiotherapy vs. Chemoradiotherapy in Non-small Cell Lung Cancer	NCT02407366	Non-small Cell ...	Icotinib Pemetrexed Carboplatin Thoracic radiot...	18 Years - 75 Years	People's Hospital of Guangxi
Erlotinib in Combination With Cetuximab	NCT00895362	Advanced Cancer...	Erlotinib Cetuximab	18 Years -	M.D. Anderson Cancer Center
Study to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer	NCT05168566	Non-small Cell ...	Sutetinib Malea...	18 Years -	Teligene US
Correlation Between EGFR Mutation Using cfDNAs and Circulating Tumor Cells in Patients With NSCLC	NCT02422628	Lung Cancer		20 Years - 85 Years	National Taiwan University Hospital
A Study Osimertinib in Patients With Stage 4 Non-small Cell Lung Cancer With Uncommon EGFR Mutations	NCT03434418	Non Small Cell ...	osimertinib	18 Years -	Duke University
Blood Sample Monitoring of Patients With EGFR Mutated Lung Cancer	NCT02284633	Lung Neoplasms		18 Years -	Aarhus University Hospital
Clinical Trial of CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLC	NCT05681780	Non Small Cell ... Stage IV Non-sm... Recurrent Non S...	Tumor-infiltrat... Nivolumab Cyclophosphamid... Fludarabine Tumor-infiltrat... Interleukin-2 (...	18 Years -	H. Lee Moffitt Cancer Center and Research Institute
Combining Afatinib and Concurrent Chemotherapy, Followed by Osimertinib and Concurrent Chemotherapy, in Untreated EGFR Positive NSCLC Tumors	NCT05298176	Non-Small Cell ...	Afatinib, Osime...	18 Years -	Amsterdam UMC, location VUmc
Preoperative Gefitinib for EGFR Mutant II-IIIa NSCLC (ECTOP-1001)	NCT01833572	Non-small-cell ...	Gefitinib	18 Years -	Fudan University
A Phase I/IB Trial of MEK162 in Combination With Erlotinib in NSCLC Harboring KRAS or EGFR Mutation	NCT01859026	Lung Cancer Non-Small Cell ...	MEK162 Erlotinib	18 Years -	H. Lee Moffitt Cancer Center and Research Institute
Osimertinib Combined With Bevacizumab in Patients With Brain Metastasis Epidermal Growth Factor Receptor (EGFR) Mutation Positive Metastatic Non-Small Cell Lung Cancer	NCT05104281	Carcinoma, Non-...	osimertinib ora...	18 Years - 90 Years	Qingdao Central Hospital
Neoadjuvant Immunotherapy in EGFR-mutant Localized NSCLC	NCT05244213	Non-small Cell ... EGFR Activating...	Sintilimab Carboplatin Nab paclitaxel	18 Years - 75 Years	Guangdong Provincial People's Hospital
First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2)	NCT05099172	Advanced Non-sm... EGFR Mutation HER2 Mutation	BAY2927088_form... BAY2927088_form... BAY2927088_form...	18 Years -	Bayer
A Study of ASP8273 in Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor-Naïve Patients With Non-Small Cell Lung Cancer Harboring EGFR Mutations	NCT02500927	EGFR-TKI-naïve ...	ASP8273 Capsule... ASP8273 Capsule...	20 Years -	Astellas Pharma Inc
Detection of EGFR Mutation in Malignant Pleural Effusion of Lung Cancer Patients and Cancer Cell Lines Establishment	NCT00752076	NSCLC	cancer cell lin...	18 Years -	National Taiwan University Hospital
Phase I Trial of Afatinib (BIBW 2992) and Dasatinib in Non-small Cell Lung Cancer (NSCLC)	NCT01999985	Lung Cancer Non-small Cell ...	Dasatinib - 1A Afatinib - 1A Dasatinib - 1B Afatinib - 1B	18 Years -	H. Lee Moffitt Cancer Center and Research Institute
Adjuvant Afatinib in Stage I-III NSCLC With EGFR Mutation	NCT01746251	Non Small Cell ...	Afatinib	18 Years -	Massachusetts General Hospital
Detecting EGFR T790M Mutations From Circulating Tumor Cells	NCT01734915	Non Small Cell ...	Circulating tum...	18 Years -	Massachusetts General Hospital
Atezolizumab and Bevacizumab in EGFR Mutant NSCLC in Patients With Progressive Disease After Receiving Osimertinib	NCT04099836	Non Small Cell ...	Atezolizumab Bevacizumab	18 Years -	Duke University
A Study of TAS3351 in NSCLC Patients With EGFRmt	NCT05765734	Non-Small Cell ...	TAS3351 oral ad...	18 Years -	Taiho Oncology, Inc.
Efficacy and Safety Study of Afatinib to Treat Lung Cancer Patients	NCT01415011	Carcinoma, Non-...	Afatinib (BIBW ...	18 Years -	University College, London
Blood Sample Monitoring of Patients With EGFR Mutated Lung Cancer	NCT02284633	Lung Neoplasms		18 Years -	Aarhus University Hospital
An Open Label Study of BIBW 2992/Afatinib in Advanced Non-Small Cell Lung Cancer Patients Pre-treated With Erlotinib or Gefitinib	NCT01932229	NSCLC	Afatinib treatm...	-	Sheba Medical Center
A Study of ASP8273 vs. Erlotinib or Gefitinib in First-line Treatment of Patients With Stage IIIB/IV Non-small Cell Lung Cancer Tumors With EGFR Activating Mutations	NCT02588261	Non-small Cell ...	naquotinib mesi... Erlotinib Gefitinib	18 Years -	Astellas Pharma Inc
Afatinib In Combination With Cisplatin Or Carboplatin + Pemetrexed In Patients With EGFR-Mutant Lung Cancers Undergoing Definitive Chemoradiation	NCT01836341	Non-small Cell ...	Afatinib Cisplatin Carboplatin Pemetrexed Radiation thera...	18 Years -	Memorial Sloan Kettering Cancer Center
Osimertinib Combined With Bevacizumab in Patients With Brain Metastasis Epidermal Growth Factor Receptor (EGFR) Mutation Positive Metastatic Non-Small Cell Lung Cancer	NCT05104281	Carcinoma, Non-...	osimertinib ora...	18 Years - 90 Years	Qingdao Central Hospital
Tislelizumab Combined With Chemotherapy With or Without Bevacizumab in TKI-Resistant EGFR-Mutated Non-squamous NSCLC	NCT04405674	Non Small Cell ...	Tislelizumab Carboplatin Pemetrexed Bevacizumab Nab paclitaxel	18 Years - 75 Years	Shanghai Chest Hospital
A Study to Learn About How Itraconazole and Carbamazepine Affect the Level of BAY2927088 in the Blood When These Drugs Are Taken Together by Healthy Participants	NCT06348888	Advanced Non-sm... EGFR Mutation HER2 Mutation Healthy Volunte...	BAY2927088 Itraconazole Carbamazepine	18 Years - 55 Years	Bayer
A Study to Learn About How BAY2927088 Affects the Level of Midazolam in the Blood When Both Drugs Are Taken Together in Healthy Participants	NCT06360211	Advanced Non-sm... EGFR Mutation HER2 Mutation Healthy Volunte...	BAY2927088 Midazolam	18 Years - 55 Years	Bayer
Preoperative Gefitinib for EGFR Mutant II-IIIa NSCLC (ECTOP-1001)	NCT01833572	Non-small-cell ...	Gefitinib	18 Years -	Fudan University
Induction Chemotherapy Followed by CCRT According to EGFR Mutation Status in NSCLC III	NCT00620269	Lung Cancer NSCLC	Erlotinib Induction or co... CCRT with IP ch... CCRT	18 Years -	National Cancer Center, Korea
SELINE: Second-Line Iressa Phase IV Study in NSCLC Patients	NCT00608868	Non Small Cell ...	Gefitinib	19 Years - 80 Years	AstraZeneca
A Study to Learn How BAY2927088 is Taken up and Handled by the Body in Healthy Male Participants	NCT06221475	Advanced Non-sm... EGFR Mutation HER2 Mutation Healthy Volunte...	BAY2927088 coat... [14C]-BAY292708... [14C]-BAY292708...	18 Years - 55 Years	Bayer
Study Comparing Bevacizumab + Erlotinib vs Erlotinib Alone as First Line Treatment of Patients With EGFR Mutated Advanced Non Squamous Non Small Cell Lung Cancer	NCT02633189	Non-squamous No...	Erlotinib Bevacizumab	18 Years - 70 Years	National Cancer Institute, Naples
First-line Treatment With Icotinib in Elder NSCLC EGFR Mutated Patients	NCT01646450	Non-Small Cell ...	Icotinib	70 Years - 80 Years	Betta Pharmaceuticals Co., Ltd.
A Study to Learn About How Food and Esomeprazole Affect the Level of BAY2927088 in the Blood When Taken Together in Healthy Participants	NCT06378658	Advanced Non-sm... EGFR Mutation HER2 Mutation Healthy Volunte...	BAY2927088 Esomeprazole Food	18 Years - 55 Years	Bayer
Adjuvant Treatment Based on MRD for EGFR Mutant NSCLC	NCT05536505	MRD	Adjuvant treatm...	18 Years - 80 Years	Guangdong Association of Clinical Trials
Preoperative Gefitinib for EGFR Mutant II-IIIa NSCLC (ECTOP-1001)	NCT01833572	Non-small-cell ...	Gefitinib	18 Years -	Fudan University

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: